Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter

IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

See all formats and pricing
More options …
Ahead of print


Telomere length determinants in childhood

Vesna Gorenjak / Alexandros M. Petrelis / Maria G. Stathopoulou / Sophie Visvikis-Siest
  • Corresponding author
  • University of Lorraine, Inserm, IGE-PCV, Nancy, France
  • Department of Internal Medicine and Geriatrics, CHU Technopôle Nancy-Brabois, Vandoeuvre-lès-Nancy, France
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2019-08-29 | DOI: https://doi.org/10.1515/cclm-2019-0235


Telomere length (TL) is a dynamic marker that reflects genetic predispositions together with the environmental conditions of an individual. It is closely related to longevity and a number of pathological conditions. Even though the extent of telomere research in children is limited compared to that of adults, there have been a substantial number of studies providing first insights into child telomere biology and determinants. Recent discoveries revealed evidence that TL is, to a great extent, determined already in childhood and that environmental conditions in adulthood have less impact than first believed. Studies have demonstrated that large inter-individual differences in TL are present among newborns and are determined by diverse factors that influence intrauterine development. The first years of child growth are associated with high cellular turnover, which results in fast shortening of telomeres. The rate of telomere loss becomes stable in early adulthood. In this review article we summarise the existing knowledge on telomere dynamics during the first years of childhood, highlighting the conditions that affect newborn TL. We also warn about the knowledge gaps that should be filled to fully understand the regulation of telomeres, in order to implement them as biomarkers for use in diagnostics or treatment.

Keywords: attrition; children; determinants; dynamics; genetics; telomere length

Introduction to telomeres

Telomeres are non-coding repetitive sequences TTAGGG on the ends of the eukaryotic chromosomes [1]. They form a protective cap that conserves the genetic material during cell division and protect it from constitutive exposure to the DNA damage response [2]. In humans, telomeres consist of 4–15 kilobase pairs (kbp) [1]. From the early research it has become clear that they shorten progressively with age [3] as a result of the end replication problem during cell division and/or oxidative stress. Chromosomes with critically short telomeres are recognised by DNA damage response proteins as damaged DNA, which leads the cell to a controlled telomere-initiated senescence [4]. When cells become senescent, they undergo morphological and genetic changes that result in the loss of tissue function.

Cells are capable of maintaining the length of telomeres with the telomerase enzyme, which is extinguished during embryonic differentiation in most somatic cells, but remains active in germline cells, activated lymphocytes and certain types of stem cell populations [5]. During normal human growth and development, telomerase activity is precisely regulated by a number of genes in order to meet the proliferative demand of the specific cellular function [6]. Cancer cells, on the other hand, can acquire the possibility of an infinite number of divisions by enhancing the telomerase activity, thus restraining the shortening of telomeres [7], or with the mechanism of the alternative lengthening of telomeres (ALT) [8].

Telomere length (TL) has been an important topic of research because of its association with longevity, as well as with the occurrence and progression of common chronic diseases. An active role of TL in age-related human diseases arises because short telomeres increase the risk of diseases related to restricted cell proliferation and tissue degradation, such as cardio-vascular diseases (CVD); long telomeres increase the risk of diseases related to increased proliferative growth, such as major cancers [9]. Therefore, TL is considered as a potential biomarker for disease susceptibility or a possible target for a particular treatment. However, its complex biology, mixed with the substantial impact of genetic and environmental factors are making this task difficult [10].

In the early 1990s, the interest in telomeres started to spread, and samples of individuals of different age ranges were used for the studies; among these were also the first samples of children. Knowing the biology behind telomeres in newborns and young children is crucial, as it provides the information about baseline TL [11]. The baseline TL represents a critically important characteristic of an individual’s telomere biology, together with a second major determinant – TL attrition over time [9]. A reduction in newborn TL can result in a greater susceptibility for pathophysiological conditions in adulthood [11].

In the following article we summarise the current knowledge of telomeres in childhood. This important period of life is characterised by dynamic biology and strong dependence on genetic and environmental factors, and it plays a crucial role in telomere attrition [12]. We demonstrate why the precise understanding of telomere dynamics in childhood is indispensable for further consideration of telomeres as a biomarker or a treatment target.

Telomeres and diseases

Telomere syndromes

TL and telomerase activity are involved in the pathology of numerous diseases [13], and preterm telomere attrition is associated with reduced longevity [14]. The initial discoveries of the role of telomeres in human diseases primarily came from the studies of rare monogenic disorders of childhood. Monogenic, age-related dysfunctions (i.e. telomere syndromes) are associated with short telomeres, normally caused by genetic mutation in a gene associated with telomere maintenance [15]. Dyskeratosis congenita (DC) is a multisystem inherited syndrome which was first related to defective telomere maintenance [16]. Children inherit short TL from affected parents, together with a mutated copy of a gene encoding products involved in telomere maintenance, such as telomerase core components (TERT and TERC), factors required for telomerase biogenesis (DKC1, NHP2, NOP2, NAF1 and PARN), telomerase trafficking (WRAP53), telomerase recruitment (ACD), telomere replication and end structure (RTEL1, CTC1, STN1 and POT1), and other aspects of telomere biology (TINF2) [17]. The three most distinguished subtypes of DC are related to the mentioned genes: X-linked recessive DC with mutations in the DKC1 gene, encoding a component of H/ACA small nucleolar ribonucleoprotein; autosomal dominant DC with heterozygous mutations in either TERC (RNA component of telomerase) or TERT (enzymatic component of telomerase); and autosomal recessive DC, for which the genes involved remain largely elusive [18]. The disease affects highly proliferative tissues, which require constant renewal and are normally highly regenerative, such as skin, gut and bone marrow [19], [20]. This leads to mucocutaneous abnormalities, abnormal nails, reticular skin pigmentation, oral leukoplakia and an increased predisposition to cancer. The principle cause of mortality of DC is bone marrow failure or aplastic anaemia; 40% of patients are affected by one of these conditions by the age of 40 [21].

Hoyeraal-Hreidarsson and Revesz syndromes are two very rare disorders with onset in infancy, are linked to very short telomeres, and represent a spectrum of the same disease. They are more severe than DC and are characterised by intrauterine growth retardation, microcephaly, cerebellar hypoplasia, progressive combined immune deficiency and aplastic anaemia. Revesz syndrome can be distinguished from Hoyeraal-Hreidarsson syndrome by the presence of bilateral exudative retinopathy [22].

Telomere disorders most commonly manifest as adult-onset diseases. Mutations in TERT and TERC can lead to diverse phenotypes in which severity depends on which family generation is affected. Idiopathic pulmonary fibrosis, for example, is normally diagnosed at the age of 50. However, later generations of a susceptible family will more often have children affected with aplastic anaemia along with classic features of DC [23].


Telomere biology is very important in paediatric cancers, as most paediatric leukaemias and embryonal solid tumours activate the telomerase enzyme. Therefore, telomeres in paediatric cancer patients are often longer than in healthy subjects, but become shorter after chemotherapeutic treatment, which causes an excessive oxidative stress that harms telomeres. Telomerase was considered as a therapeutic target for paediatric cancers, as the enzyme plays a key role in conferring cellular immortality, is present in most tumours, and is relatively specific for cancer cells [24], [25], [26]. Despite all the efforts to develop a telomerase-targeting therapy, there is currently no approved treatment available on the market [27]. This is mainly due to the high number of cell doublings required to induce a tumour suppressive senescence after telomerase inhibition – a long period before a telomerase inhibitor becomes effective against a tumour [28]. In addition, such treatment could prompt a toxic effect on highly proliferative normal stem cells that can express a regulated telomerase activity [29]. A Mendelian randomisation study on the association between TL and risk of cancer and non-neoplastic diseases showed that increased TL due to germline genetic variation was generally associated with increased risk for site-specific cancers, but reduces the risk for some non-neoplastic diseases, including CVD [30]. Therefore, potential therapeutic applications based on TL should be carefully considered also for the trade-off of the risk for going from one disease to another.

Stress and other diseases

Many childhood clinical disorders can cause increased oxidative stress and chronic inflammation, including perinatal brain damage, asthma, cystic fibrosis, juvenile rheumatoid arthritis, cholestatic liver diseases and diarrhoeal diseases [31]. Chronic inflammation can increase the rate of cell proliferation and increase cellular turnover, therefore facilitating telomere erosion. Also, oxidative stress can increase the size of telomere repeats clipped from the ends of chromosomes, thus promoting telomere DNA double-strand breakage and telomere shortening [32]. Long-term childhood diseases that provoke an increased oxidative stress can therefore cause faster telomere shortening and result in accelerated cellular ageing that may manifest in adulthood as a common age-related pathology [33], [34], [35], [36].

It was demonstrated that in childhood, stress originating from childhood maltreatment [37] or violence [38] can cause a premature shortening of telomeres [39]. Similarly, maternal stress during pregnancy can have an impact on TL in children. This subject will be further discussed in the section “Determinants of newborn TL”.

Genetic determinants of TL

TL is a highly heritable trait (36%–86% in different family and twin studies) [40], [41], [42], [43], [44], [45]. Several large genome-wide association studies (GWAS) were performed to investigate associations between genetic variants and relative TL in an adult population [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56]. Most of the identified SNPs harbor genes that encode proteins with known functions in telomere biology (i.e. genes directly involved in telomere maintenance). Two GWAS studies were performed in paediatric populations to look for common SNPs related to relative TL (Table 1), and none replicated the results identified in adult cohorts. This suggests that possibly other genetic variants are involved in the regulation of TL in childhood and adolescence than in adulthood [57], [58]. Moreover, none of the identified SNPs was replicated among paediatric populations. One of the possible reasons for this might be the heterogeneity between populations, as studies were performed in healthy African-American children and adolescents [57] and in a healthy European population [58]. Genotyping of the SNPs identified in the European cohort was also performed in newborns in an Asian population, but no significant association for any individual variant was detected [59].

Table 1:

Genetic variants associated with relative TL in children population.

There is no doubt that genes related to telomere biology have a big impact on TL starting at birth; a pure example is the heritable childhood disease DC as discussed already [20]. However, individuals with such diseases are born with the very short telomeres, inherited by their parents, whereas the impact of affected genes can show only later in life. Accelerated loss of telomere base pairs after birth, caused by affected genes, might not be evident in the first decades of life, but would only become significant in adulthood.

The GWAS on paediatric populations are interesting for the identification of genes that reflect the baseline TL before the occurrence of the major attrition. However, paediatric studies to date have used small sample sizes compared to studies in adult cohorts. In order to confirm whether there is an age-specific variation of genetic factors contributing to TL regulation, and to identify novel variants that regulate TL in childhood, larger GWAS studies should be performed on the paediatric population.

Assessment of TL in healthy and diseased neonates and children

In the following section we will present the studies that focussed on determination of newborn TL and rate of TL attrition throughout childhood (Table 2) and summarise the important conclusions acquired from the researchers.

Table 2:

Studies assessing the TL dynamics in newborns and children.

One of the first investigations that used a paediatric sample to study TL dates from 1993. The study compared lymphocyte TL of 21 individuals with Down syndrome (DS), aged 0–45 years, to 119 healthy controls aged 0–107 years. The rate of telomere loss was calculated as the decrease in mean telomere restriction fragment (TRF) length as a function of donor age. The study demonstrated that DS patients experience significantly higher rates of telomere loss (133±15 bp/year) compared to healthy age-matched controls (41±7 bp/year). Moreover, separation of samples according to gender showed faster rates of male telomere loss compared to female, but the difference was not statistically significant. The difference in the rate of TL shortening from birth until adulthood was not discussed [60].

The first study to focus on the rate of telomere sequence loss in children’s leucocytes was published by Frenck et al. in 1998. The research was conducted on 75 individuals that comprised 12 unrelated healthy newborns and their relatives (parents, grandparents). Comparison among three generations showed a larger difference in TL between the newborns and their parents (4.8 kbp) than between parents and grandparents (2.0 kbp), even though the age interval was similar for both generations (25 years). Further research was conducted in order to observe the rate of telomere shortening during the first few years of life. Because of a disagreement of the Institutional Review board, the study could not provide the follow-up of the same children, but it compared 10 unrelated healthy children of age 5–48 months. Researchers discovered that the rate of telomere shortening is not stable, but appears in three characteristic phases: (1) from birth to the age of 4, characterised by a rapid decline in the average TL, (2) stable TL from the age of 4 until early adulthood, (3) gradual decline in mean TL associated with advancing age. The authors assumed that a high rate of proliferation appears in the most immature subset of haematopoietic progenitors in the first months of life. Haematopoiesis throughout life is later initiated from progenitors that have already undergone a substantial amount of telomeric loss [61]. The weak point of the study was a low number of the individuals (10 children) by which the whole theory was estimated. It is important to mention that variation in TL among newborns is as wide as the variation among adults [12]. Therefore, comparisons between non-related children of different ages might not perfectly describe the process of telomere shortening that is happening in the same individual, as inter-individual differences between the subjects of the same age can be significant and could cause biased results when using a small sample size.

This problem was overcome in the study published by Zeichner et al. in 1999, in which nine newborns of HIV-infected mothers were followed up for 3 years. Two adults with the risk of HIV infection with 8- and 10-year follow-up were used for comparison. The study detected a significant difference between TL measured in peripheral blood mononuclear cells (PBMCs) at 1 month and 36 months of age. The average rate for the TL shortening was 270 bp/year from 0 to 36 months, which was significantly higher than telomere loss in adult PBMCs (50 bp/year). Compared to Frenck et al., Zeichner et al. reported only two characteristic phases of telomere loss: (1) a phase of fast telomere sequence loss in the first 3 years, followed by (2) a relatively constant gradual loss of telomere base pairs [62]. The strong point of the study was the longitudinal follow-up of individuals, which enabled a much more refined view of telomere biology than cross-sectional studies. However, the follow-up of the children was conducted only until the age of 3, and the researchers estimated the telomere loss after the age of 3 by calculating the average age loss from the last two samples obtained from each child. The calculated value for the telomere loss was 50 bp/year, consistent with the results in adults; therefore, researchers assumed that from the age of 3 onward the telomere loss is constant [62].

The plateau of TL at the age of 4, first mentioned by Frenck et al., was further investigated in 70 children of Latino origin. Leucocyte telomere length (LTL) was assessed twice in a year, at the age of 4 and 5. The study reported LTL maintenance in most of the children during the period of 1 year, which is consistent with the results obtained by Frenck et al. [61].

In order to have an insight into foetal haematopoiesis and telomere attrition, changes in LTL were also investigated in preterm and full-term newborns. The findings of the cord blood TRF analysis of 15 preterm and 11 full-term newborns showed no significant differences between the groups, though a trend of shorter telomeres with increasing gestational age was observed. A rapid and significant decline between 27 and 32 weeks of gestation was noticed, pointing to an increased proliferation rate during this period of gestation. Moreover, after 32 weeks of gestation a high inter-individual variability of LTL was observed, possibly due to an important genetic influence on TL, as estimated by the researchers [63].

On the contrary, most other studies observed significant differences in preterm and full-term newborn TL. Vasu et al. confirmed that preterm infants had longer LTL than full-term newborns and that relative LTL is highly variable among newborn infants. In addition, they discovered that at birth, preterm infants had significantly longer LTL than full-term babies [66]. Holmes explained that the difference occurs because of the greater proliferative capacity of foetal haematopoietic stem cells in comparison to post-natal stem cells [67].

Finally, telomeres were also assessed in small-for-gestational-age (SGA) babies; however, there was no difference in comparison to normally grown controls [64].

All but two of the mentioned studies used TRF technique for measurement of TL (Table 2). A real-time PCR (qPCR) technique for TL measurement is a less precise method than TRF, and it might impact the obtained results [68]. The newborn’s blood was in all cases collected from the umbilical cord, and TL was measured from blood leukocytes or PBMCs. All studies have substantial limitations due to the small sample size and/or lack of longitudinal observations. However, ethical considerations of such studies limit the research design, as it is unethical to follow-up healthy children for research that will not contribute to health improvement [61]. Hence, the follow-up was possible only in the cases of children with significant health risk (such as preterm babies and children of HIV-infected mothers), where closer medical follow-up was indispensable.

Nevertheless, some final conclusions can be drawn for TL dynamics in children:

  • TL is highly variable among children of the same age.

  • Preterm babies have longer telomeres than full-term babies.

  • The rate of telomere loss is higher in the first 3 years of life (approximately 250 bp/year).

  • The TL at the age of 3 until young adulthood might be stable, but it is more likely gradually decreasing (up to 50 bp/year).

  • The rate of telomere loss becomes constant in young adulthood (approximately 50 bp/year).

  • The differences in shortening rates at different periods of childhood are due to an increased cell replication rate in infants, especially during accelerated development of the immune system (expanding of haematopoietic stem cell [HSC] pool).

TL shortening in diverse tissues

In the following section we will discuss the difference in TL among various human tissues. Different views on the topic will be presented and the most pertinent conclusions will be pointed out.

Several studies have agreed that synchrony in TL exists among tissues of the human foetus, but this is lost during extrauterine life [69], [70]. Corresponding to this idea, TL in samples of three tested tissues in newborns (leucocytes, umbilical artery cells and skin cells) were found to be highly synchronised [12]. Indeed, telomerase is active during every stage of development of the embryo, and this enables the maintenance of equally long telomeres [71].

With ageing, cells in different tissues lose the synchrony in TL due to different proliferative activity, which mainly arises during the expanded growth and development in the first two decades of life. For a long time, there was a common opinion that TL in skeletal cells, which form a minimally proliferative tissue, represents the approximate size of TL at birth [72], [73]. Decary et al. demonstrated that skeletal satellite cells lose both proliferative capacity and TL during the first two decades of life. In adulthood, muscle development is complete and TL becomes stable. On the other hand, they realised that skeletal muscle cell myonuclei, generally presented as post-mitotic tissue, do not undergo any shortening of telomeres and stay consistent from birth to late age [73].

Scientists thus assumed that TL in skeletal muscle and the difference between LTL and skeletal muscle telomere length (MTL) could provide a broad account of LTL dynamics over the life course of the individual, as these two variables would represent birth LTL and its age-dependent attrition, respectively [74]. They concluded that the difference between TL in muscle and leucocytes provides a much better account for LTL dynamics than LTL alone (research was performed in dogs) [74].

The research in adult subjects, however, gave unexpected results. TL shortening in four types of somatic tissue cells – leucocytes, muscle, skin and fat – was examined in 87 individuals with an age range of 19–77 years. Despite different replicative status, all tissues displayed similar rates of age-dependent attrition. The difference in TL across the tissues is thus believed to be established during the first two decades of life. Later, stem cell division rates, including those of muscle, are synchronised across the examined somatic tissues. Muscle cells are therefore not an exact indicator of birth TL, which continuously shortens even in adulthood [75]. The authors explained this discovery, which is not consistent with the previous studies of TL in skeletal muscle, as the result of a more accurate method of TL measurement and a bigger sample size used for the investigation.

The difference between skeletal MTL and LTL is primarily an index of HSC telomere shortening due to the expansion of the HSC pool, which becomes stable in adulthood. Some differences in proliferative activities among two tissues can appear but are likely to be modest [76].

Finally, the difference between skeletal MTL and LTL was examined in the foetal and child samples. Surprisingly, the study demonstrated that MTL is longer than LTL already in foetal samples, assuming that TL is similar across tissues only until early embryonic development. Scientists concluded that variation in TL among individuals is wider than intra-individual variation of LTL and MTL, and that individuals with short/long MTL display short/long LTL, as was previously shown [77].

Different tissue cells display different proliferative activities. However, this difference is mainly established until adulthood, when cells require only a small number of divisions to maintain tissue integrity [75].

The main conclusions of the above discussed studies are the following:

  • During embryonic development, cells of different tissues have similar TL due to the activity of telomerase in early intrauterine growth.

  • The difference in TL among tissues (e.g. skeletal muscle and leucocytes) appears during late intrauterine development and is mainly established in the first two decades of life.

  • TL of minimally proliferative muscle cells shortens much more slowly than TL of highly proliferative leucocyte cells during the first two decades of life.

  • In adulthood, skin, fat, muscle and leucocyte cell TL shortening is synchronized.

  • The difference in MTL and LTL represents the leucocyte telomere dynamics during early life and corresponds well to telomere dynamics of an individual.

  • High LTL variability among individuals is expressed already in utero.

  • Variation in TL between foetuses and children is as wide as variation among adults of the same age.

  • In the same child or adult, a synchrony exists across somatic tissues (an individual with long LTL will have long MTL).

Determinants of newborn TL

As previously mentioned, since birth, a high variability exists in TL among children. One of the most important factors that determine this inter-individual difference is genetics, which was shown in several heritability studies [40], [41], [42], [43], [44], [45]. Nevertheless, a substantial number of studies in adult cohorts showed that besides genetics, TL can be influenced by various other factors. Most commonly reported among those are:

  • Gender (women have longer TL than men) [78]

  • Race (African Americans have longer TL than Europeans) [79], [80]

  • Paternal age (older age of the father is associated with longer TL) [81], [82]

  • Smoking (smokers have shorter TL than non-smokers) [83], [84]

  • Physical activity (non-active have shorter TL than active) [85]

  • Traumatic events (cause shortening of TL) [39], [86], [87], [88]

  • Obesity (causes shortening of TL) [84]

  • Oxidative stress (causes shortening of TL) [89], [90].

Antenatal determinants were shown to be a particularly important factor of TL, as early developmental environment conditions the developmental process, which in turn influences the individual’s predisposition to developing a complex common disorder [91]. TL in children can be affected by oxidative, immune, endocrine and metabolic pathways in a way that accelerates cellular dysfunction over the lifespan [11], [92], thus reflecting the effect of specific conditions on the later susceptibility to a disease. Maternal stress [93], [94], [95], hormones [96], smoking [97], race [98], vitamin concentrations [99], [100], pre-pregnancy body mass index (BMI) [101] and other factors showed correlation with TL and pointed out the importance of in utero exposures in the regulation of newborn TL. In this section we will focus on some of the most pertinent antenatal determinants. The summary of the newborn TL determinants is presented in Table 3.

Table 3:

Determinants of newborn TL.


The fact that women have a predisposition for longer telomeres than men have is well known and has been systematically confirmed in adult telomere studies [78], [110], [111]. At the beginning of the exploration, studies of telomeres in children did not take into account the gender of the individuals or any other covariate that could impact TL. The first study to focus on newborn gender in association with TL showed that at birth, male (10.95±0.088 kb) and female (11.07±0.077 kb, p=0.3) newborns do not statistically differ in the length of their leucocyte telomeres, suggesting that sex difference in TL arises from different rates of attrition in extrauterine life [12]. This discovery was not in accordance with later studies [103], [112], and the reason for this discrepancy might be that no other potential TL determinant (race, socioeconomic status, etc.) was taken into account.

On the contrary, longer cord blood and placental telomeres were found in female newborns compared to male newborns in studies of Latino and mixed-population infants [102], [109], supposing that hormonal differences between male and female genders could play a role in telomere dynamics in utero [113].

It is possible that the impact of gender on TL is smaller in newborns than in adults of the same age. However, it remains an important determinant that should be systematically considered in all telomere studies. The degree of the gender impact on infant TL remains to be fully investigated.


The explanation for differences in TL among different races lies in natural protection developed during the evolution process. The hypothesis is that a cell division limit was developed as a mechanism for tumour suppression [28]. Therefore, the presence of relatively shorter TL in Europeans is a result of polygenic adaptation of the northbound migration out of equatorial Africa that attenuated the risk of melanoma in individuals with light skin pigmentation [79]. TL was compared among 71 Black and White babies, measured in blood spots of newborns. The results showed that infant TL was significantly longer in Black compared to White newborns (p=0.0134), in a model accounting for sex, birth date, birth weight, gestational age, parental age, maternal race and maternal highest level of education as a proxy for socioeconomic status [103]. This study demonstrated that racial differences in TL are significant from birth and highlighted origin as an important TL determinant.


Two studies give an example of the importance of appropriate maternal vitamin intake during pregnancy. First, maternal folate concentration was measured in the first trimester of pregnancy in serum samples of 119 mothers and was analysed in relation to TL measured from the cord blood mononuclear cells [100]. Adjusted covariates were specified a priori, including maternal socioeconomic status (annual family income), race/ethnicity, maternal pre-pregnancy BMI, the presence of obstetric complications, maternal age, infant sex, gestational age at birth and birth weight. The results demonstrated that each 10 ng/mL increase in maternal total folate concentration was associated with a 5.8% increase in median TL (p=0.03).

Second, maternal vitamin D concentration was examined for associations with LTL in newborn cord blood samples in a model adjusted for the maternal age, BMI, LTL, white blood cell count, glycosylated haemoglobin level, health behaviours (smoking, exercise, body weight before pregnancy, medical history) and nutritional intake and for the newborn’s sex and birthweight. The study concluded that maternal vitamin D levels were also positively associated with newborn LTL [99].

Maternal pre-pregnancy BMI

Maternal obesity during pregnancy can reflect an adverse nutritional status that affects an offspring and has a significant deleterious effect on the outcome of pregnancy [114]. This phenomenon was also observed in telomeres. Higher maternal pre-pregnancy BMI was associated with a decline in newborn TL in a study examining 743 samples from cord blood and 702 samples from placental tissue, independent of maternal and paternal age at birth, maternal education, gestational age, newborn’s gender, ethnicity, birthweight, maternal smoking status, parity, caesarean section and pregnancy complications. Each kg/m2 increase in pre-pregnancy BMI was associated with a −0.50% (95% CI, −0.83 to −0.17; p=0.003) shorter cord blood TL and a −0.66% (95% CI, −1.06 to −0.25; p=0.002) shorter placental TL [101]. Higher maternal pre-pregnancy BMI was also associated with increased newborn adiposity and inflammation [115]. Nonetheless, with adequate preventive measures maternal obesity could be reduced. This would result in decreased pregnancy complications and might also impact the overall quality of the child’s life.

Maternal stress

Stress plays an important role in foetal development and can result in an altered endocrine and immune response, which serve in the progression of normal gestation. This results in increased oxidative stress that is particularly harmful for telomeres [91]. Psychological stress and psychiatric disorders were previously linked to telomere biology in adults [37], [39], [116], [117]. The significant impact of intrauterine stress exposure on LTL was first demonstrated in young adults [118]. The fact that exposure to maternal psychosocial stress may exert a “programming” effect on the newborn telomere biology was confirmed in 27 mother-newborn dyads, after accounting for the mother’s age at birth, weight, sex and exposure to antepartum obstetric complications. The effect of the pregnancy-specific stress on newborn LTL accounted for 25% of the variance in LTL [104]. Likewise, a significant negative association between maternal stress and newborn TL was observed in a group of 24 mother-newborn dyads. Affected newborns had significantly shorter TL (6.98±0.41 kb) measured in cord blood cells, compared to the newborns of mothers with low stress (8.74±0.24 kb; t=−3.99, p=0.003) [94]. Finally, it was demonstrated that maternal lifetime history of a psychiatric disorder causes shortening of maternal TL but does not affect newborn TL. Acute stress during pregnancy, on the other hand, is related to shorter TL of a newborn but does not affect the mother’s TL [95].


A recent systematic review and meta-analysis demonstrated that TL of smokers decreases significantly over time in contrast to non-smokers [119], which implies mechanisms linking tobacco smoke exposure to ageing-related diseases. The impact of intrauterine tobacco exposure on foetal TL was also investigated. First, a study of the effect of cigarette smoking during pregnancy on the lymphocyte subpopulations in newborns showed that newborns of smoking mothers had significantly longer telomeres compared to newborns of non-smoking mothers [97]. This unexpected discovery was disproved in a study by Salihu et al. in which evidence of a positive association between shortened LTL and smoking during pregnancy was demonstrated [105], suggesting the possibility of early intrauterine programming for accelerated ageing as a result of tobacco exposure. The reason for the discrepancy in the results of these two studies is not clear; however, there is undeniable proof that link cigarette smoke to telomere shortening caused by increased oxidation stress in cells [120]. We therefore postulate that smoking during pregnancy should be considered as an important environmental factor that causes accelerated chromosomal ageing via increased telomere loss.


The hormones have a substantial effect on adult male and female TL, and the impact of hormonal therapy was a subject of numerous studies [121], [122]. Entringer et al. assessed the influence of estriol (E3) concentration in early gestation on children’s TL. TL was measured in buccal cells collected in children aged 14.6 months on average. After accounting for the effects of gestational age at maternal blood draw during pregnancy and the child’s age and sex, there was a significant, independent effect of maternal E3 concentrations on children’s TL [96].

Gestational and pre-gestational diabetes

Association studies of a mother’s gestational or pre-gestational diabetes with TL showed inconsistent results. First, Cross et al. compared TL of cord blood mononuclear cells of newborns, whose mothers suffered from pre-gestational type 1 diabetes (n=26), type 2 diabetes (n=20) or gestational diabetes (n=71), with newborns of mothers without diabetes (n=45, n=76 and n=81, respectively) [106]. Covariates included maternal smoking status, age of both parents, and offspring’s birth weight and sex. The study found no difference in cord blood TL in pregnancies of women with diabetes compared to control subjects, but it identified higher cord blood telomerase activity in type 1 and gestational diabetes. Similarly, a study of 20 cases of mothers with gestational diabetes and 14 cases of pre-gestational diabetes (n=7 type 1 and n=7 type 2) compared to 18 control mother-baby pairs also showed no significant difference in the newborn’s cord blood TL [108]. On the other hand, another study demonstrated that a group of babies born to mothers with gestational diabetes (n=82) had significantly shorter LTL than babies born to healthy mothers (p=0.028). The model was adjusted for maternal age, gestational age at delivery, neonatal birth weight and foetal gender [107]. In conclusion, further studies should be performed to confirm the impact of gestational or pre-gestational diabetes on newborn TL.

Paternal age at conception

Finally, one of the most intriguing observations regarding TL is the fact that children with older fathers have longer telomeres in comparison to their peers with younger fathers. The effect of paternal age at conception (PAC) was also demonstrated in newborns, where a 1-year increase in PAC corresponded to a 0.016 kb increase of newborn LTL [109]. This phenomenon was attributed to elongation of telomeres in the sperm of older men due to a higher telomerase activity [81], [123]. Studies remain inconclusive whether it is maternal or paternal inheritance that has a greater impact on TL; however, the effects of both are already evident in newborns [92].

To conclude, Entringer et al. understood the process of newborn TL development as a foetal programming of health and disease risk: ‘… intrauterine life represents a particularly sensitive time period when the effects of maternal states and conditions around conception and across pregnancy may be transmitted to the developing embryo/foetus.’ TL is a key cellular target of these effects and carries important implications in long-term health and susceptibility to common age-related disorders [11].


During the last three decades, extensive studies were continually providing the evidences that linked shortened telomeres with common age-related diseases, disease risk factors and longevity. Telomeres were considered as a potential biomarker that could assess susceptibility to a specific pathology, or even as a mitotic clock that would limit cell life span and predict one’s longevity. Even though there are reasonable explanations behind these theories, there is still missing knowledge in telomere biology that is restraining the implementation of telomeres as biomarkers in clinical practice.

Only recently, scientists agreed that the best model to describe telomere dynamics is not simply measuring TL per se, but determining baseline (newborn) TL and telomere attrition over time and how it is affected by the number of cell divisions, oxidative stress and other exposures that may reduce TL.

Baseline TL of newborns significantly differs among individuals, corresponding to the variation of TL found among adults of the same age. Twin studies, however, showed a synchrony among TL in siblings and therefore provided proof of strong genetic determination of telomere biology. Genetic influence on TL was confirmed with the identification of genetic variants that were significantly related to TL in adult cohorts. Surprisingly, GWAS in the child population did not identify the same significant variants, implying that genetic regulation of TL could be age dependent. Genetic loci detected in adult studies probably modify TL over the life span, while different genetic mechanisms affect the TL of newborns.

Baseline TL significantly differs also among foetuses of the same gestational age. During early intrauterine life, cells divide excessively but maintain their TL with the telomerase enzyme. This results in a synchrony of TL among cells of different tissues within the same individual. The telomerase activity is mainly extinguished after early embryonic development, and telomeres of cells with different proliferating activities start to shorten at different rates. Because leucocytes represent highly proliferative tissue with a high rate of turnover compared to minimally proliferative muscle cells, a shorter LTL of a full-term newborn compared to the MTL of the same individual can be detected.

Cumulative risk exposures, especially during early life, together with genetic make-up account for the likelihood of developing a common age-related pathology. During intrauterine development, the foetus is continuously exposed to numerous environmental factors which can transfer through distinct biological pathways and affect baseline TL in a process of so-called foetal programming. Baseline TL reflects the early environmental conditions and represents an important cellular marker for susceptibility to common age-related pathologies. TL attrition can accelerate under conditions that cause increased oxidative stress and chronic inflammation and can determine newborn TL during pregnancy. Some of the unfavourable conditions can be modified: avoiding smoking during pregnancy, maintaining appropriate BMI before and during pregnancy, and ensuring a proper vitamin intake. Therefore, it is important to be aware of the influence of such conditions on the child’s health. Maternal stress and gestational diabetes are less easily avoided but can be managed with proper clinical help. Finally, some of the determinants of newborn TL, such as the child’s sex, race or genetics cannot be modified, but it is important to understand and take into account their impact on TL, especially in designing the studies exploring new telomere determinants or association of telomeres with pathologies.

Besides baseline TL, telomere attrition over time represents another important element in telomere dynamics. However, telomeric sequence loss is not constant throughout life; the first 4 years of childhood are characterised by a rapid decline in TL due to a large turnover of highly proliferative cells. In this period, the main difference in TL of tissues with different proliferative capacities is established. Later, telomeres in most cells are gradually and synchronically shortened. The variance among cells in different tissues of an individual can be significant, but it remains smaller than the variance in TL among unrelated individuals.

The dynamics of TL between 4 years of age and early adulthood remain to be elucidated. Some discoveries suggest that telomeres during this life period reach a plateau and maintain their length, whereas other results point to a gradual shortening of approximately 50 bp/year that starts after the age of 4 and remains stable throughout life. Indeed, the biggest problem of the first studies of TL in children and newborns is the small sample size and the lack of longitudinal follow-up. Despite that, these studies made some consistent conclusions which provided the first insights into telomere dynamics from the first phases of gestation until adulthood. TL at birth reflects TL in adulthood: children with short telomeres will most likely grow into adults with short telomeres. Environmental factors in adulthood may affect TL, but this influence is probably smaller than in the dynamics at birth and in the first years of life.

Knowing the importance of TL in childhood, it is crucial to have a good understanding of the dynamics of telomeres in intrauterine life and in the first years of life. This could help to prevent early attrition and thus decrease the risk for later pathophysiological conditions. It is important to keep in mind that the spectrum of diseases related to relative TL in adulthood is vast, and though these pathologies manifest only in adulthood, early developmental environment plays a significant role in their generation.

In view of this, we can conclude that there are still some missing gaps that need further exploration for a general understanding of telomere biology. First, larger genetics studies in the child population are warranted to detect genetic variants that influence baseline TL. This may result in the discovery of novel genetic loci involved in the pathways of telomere biology and help understanding biological regulation of telomere length in childhood. Second, longitudinal studies on telomere dynamics from birth until adulthood are necessary. Follow-up of individuals through long periods would give answers to the missing information of telomere dynamics after the age of 4 and would confirm the effects of early environmental conditions on adult susceptibility to common diseases. Finally, new studies on newborn telomere determinants are required, to confirm previously discovered relations and to find new potential conditions that significantly influence newborn TL.

With precise knowledge of the biology and dynamics of telomeres, we might expect that one day TL will be used as a common biomarker in everyday clinical practice.


Many thanks to Prof. Dr. Georges Weryha for his motivation for this project and kind discussions around it.


  • 1.

    Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA 1988;85:6622–6. CrossrefGoogle Scholar

  • 2.

    O’Sullivan RJ, Karlseder J. Telomeres: protecting chromosomes against genome instability. Nat Rev Mol Cell Biol 2010;11: 171–81. CrossrefPubMedGoogle Scholar

  • 3.

    Lindsey J, McGill NI, Lindsey LA, Green DK, Cooke HJ. In vivo loss of telomeric repeats with age in humans. Mutat Res 1991;256:45–8. PubMedCrossrefGoogle Scholar

  • 4.

    Fagagna FD, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, von Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003;426:194. CrossrefPubMedGoogle Scholar

  • 5.

    Hiyama E, Hiyama K. Telomere and telomerase in stem cells. Br J Cancer 2007;96:1020. CrossrefPubMedGoogle Scholar

  • 6.

    Cong Y-S, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol Rev 2002;66:407–25. PubMedCrossrefGoogle Scholar

  • 7.

    Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PD, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011–5. PubMedCrossrefGoogle Scholar

  • 8.

    Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet 2010;11:319. PubMedCrossrefGoogle Scholar

  • 9.

    Aviv A, Shay JW. Reflections on telomere dynamics and ageing-related diseases in humans. Proc R Soc Lond B Biol Sci 2018;373:20160436. CrossrefGoogle Scholar

  • 10.

    Gorenjak V, Akbar S, Stathopoulou MG, Visvikis-Siest S. The future of telomere length in personalized medicine. Front Biosci (Landmark Ed) 2018;23:1628–54. PubMedCrossrefGoogle Scholar

  • 11.

    Entringer S, de Punder K, Buss C, Wadhwa PD. The fetal programming of telomere biology hypothesis: an update. Proc R Soc Lond B Biol Sci 2018;373:20170151. CrossrefGoogle Scholar

  • 12.

    Okuda K, Bardeguez A, Gardner JP, Rodriguez P, Ganesh V, Kimura M, et al. Telomere length in the newborn. Pediatr Res 2002;52:377–81. PubMedCrossrefGoogle Scholar

  • 13.

    Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 2005;6:611–22. PubMedCrossrefGoogle Scholar

  • 14.

    Tzanetakou IP, Nzietchueng R, Perrea DN, Benetos A. Telomeres and their role in aging and longevity. Curr Vasc Pharmacol 2014;12:726–34. PubMedGoogle Scholar

  • 15.

    Armanios M, Blackburn EH. The telomere syndromes. Nat Rev Genet 2012;13:693–704. PubMedCrossrefGoogle Scholar

  • 16.

    Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program 2011;2011:480–6. CrossrefPubMedGoogle Scholar

  • 17.

    Dodson L, Bertuch AA. Dyskeratosis congenita and the telomere biology disorders. In: Kupfer G, Reaman G, Smith F, editors. Bone marrow failure. Cham: Springer, 2018:111–35. Google Scholar

  • 18.

    Kirwan M, Dokal I. Dyskeratosis congenita: a genetic disorder of many faces. Clin Genet 2008;73:103–12. PubMedGoogle Scholar

  • 19.

    Shay JW, Wright WE. Telomeres in dyskeratosis congenita. Nat Genet 2004;36:437–8. PubMedCrossrefGoogle Scholar

  • 20.

    Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999;402:551–5. PubMedCrossrefGoogle Scholar

  • 21.

    Dokal I. A disease of premature ageing. Lancet 2001;358:S27. PubMedCrossrefGoogle Scholar

  • 22.

    Glousker G, Touzot F, Revy P, Tzfati Y, Savage SA. Unraveling the pathogenesis of Hoyeraal-Hreidarsson syndrome, a complex telomere biology disorder. Br J Haematol 2015;170:457–71. CrossrefPubMedGoogle Scholar

  • 23.

    Armanios M. Syndromes of telomere shortening. Annu Rev Genomics Hum Genet 2009;10:45–61. CrossrefPubMedGoogle Scholar

  • 24.

    Engelhardt M, Ozkaynak MF, Drullinsky P, Sandoval C, Tugal O, Jayabose S, et al. Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. Leukemia 1998;12:13–24. CrossrefPubMedGoogle Scholar

  • 25.

    Tabori U, Dome JS. Telomere biology of pediatric cancer. Cancer Invest 2007;25:197–208. CrossrefPubMedGoogle Scholar

  • 26.

    Beeharry N, Broccoli D. Telomere dynamics in response to chemotherapy. Curr Mol Med 2005;5:187–96. CrossrefPubMedGoogle Scholar

  • 27.

    Shay JW, Wright WE. Telomeres and telomerase: three decades of progress. Nat Rev Genet 2019;20:299–309. PubMedCrossrefGoogle Scholar

  • 28.

    Jager K, Walter M. Therapeutic targeting of telomerase. Genes (Basel) 2016;7:39. Google Scholar

  • 29.

    Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov 2006;5:577–84. CrossrefPubMedGoogle Scholar

  • 30.

    Haycock PC, Burgess S, Nounu A, Zheng J, Okoli GN, Bowden J, et al. Association between telomere length and risk of cancer and non-neoplastic diseases: a Mendelian randomization study. JAMA Oncol 2017;3:636–51. CrossrefGoogle Scholar

  • 31.

    Granot E, Kohen R. Oxidative stress in childhood – in health and disease states. Clin Nutr 2004;23:3–11. CrossrefPubMedGoogle Scholar

  • 32.

    Poonpet T, Saetan N, Tanavalee A, Wilairatana V, Yuktanandana P, Honsawek S. Association between leukocyte telomere length and angiogenic cytokines in knee osteoarthritis. Int J Rheum Dis 2018;21:118–25. PubMedCrossrefGoogle Scholar

  • 33.

    Belsky DW, Shalev I, Sears MR, Hancox RJ, Lee Harrington H, Houts R, et al. Is chronic asthma associated with shorter leukocyte telomere length at midlife? Am J Respir Crit Care Med 2014;190:384–91. CrossrefPubMedGoogle Scholar

  • 34.

    Li J, Tang B, Qu Y, Mu D. Telomerase reverse transcriptase: a novel neuroprotective mechanism involved in neonatal hypoxic-ischemic brain injury. Int J Dev Neurosci 2011;29:867–72. PubMedCrossrefGoogle Scholar

  • 35.

    Eisenberg DT, Borja JB, Hayes MG, Kuzawa CW. Early life infection, but not breastfeeding, predicts adult blood telomere lengths in the Philippines. Am J Hum Biol 2017;29:e22962. Google Scholar

  • 36.

    Picarelli MM, Danzmann LC, Grun LK, Junior NT, Lavandovsky P, Guma F, et al. Arterial stiffness by oscillometric device and telomere length in juvenile idiopathic artrhitis with no cardiovascular risk factors: a cross-sectional study. Pediatr Rheumatol Online J 2017;15:34. PubMedCrossrefGoogle Scholar

  • 37.

    Tyrka AR, Price LH, Kao H-T, Porton B, Marsella SA, CarpenterLL. Childhood maltreatment and telomere shortening: preliminary support for an effect of early stress on cellular aging. Biol Psychiatry 2010;67:531–4. CrossrefPubMedGoogle Scholar

  • 38.

    Moffitt TE. Childhood exposure to violence and lifelong health: clinical intervention science and stress-biology research join forces. Dev Psychopathol 2013;25:1619–34. PubMedCrossrefGoogle Scholar

  • 39.

    Price LH, Kao H-T, Burgers DE, Carpenter LL, Tyrka AR. Telomeres and early-life stress: an overview. Biol Psychiatry 2013;73: 15–23. PubMedCrossrefGoogle Scholar

  • 40.

    Andrew T, Aviv A, Falchi M, Surdulescu GL, Gardner JP, Lu X, et al. Mapping genetic loci that determine leukocyte telomere length in a large sample of unselected female sibling pairs. Am J Hum Genet 2006;78:480–6. CrossrefGoogle Scholar

  • 41.

    Atzmon G, Cho M, Cawthon RM, Budagov T, Katz M, Yang X, et al. Evolution in health and medicine Sackler colloquium: genetic variation in human telomerase is associated with telomere length in Ashkenazi centenarians. Proc Natl Acad Sci USA 2010;107(Suppl 1):1710–7. CrossrefGoogle Scholar

  • 42.

    Bakaysa SL, Mucci LA, Slagboom PE, Boomsma DI, McClearn GE, Johansson B, et al. Telomere length predicts survival independent of genetic influences. Aging Cell 2007;6:769–74. CrossrefPubMedGoogle Scholar

  • 43.

    Vasa-Nicotera M, Brouilette S, Mangino M, Thompson JR, Braund P, Clemitson J-R, et al. Mapping of a major locus that determines telomere length in humans. Am J Hum Genet 2005;76:147–51. CrossrefGoogle Scholar

  • 44.

    Slagboom PE, Droog S, Boomsma DI. Genetic determination of telomere size in humans: a twin study of three age groups. Am J Hum Genet 1994;55:876–82. PubMedGoogle Scholar

  • 45.

    Njajou OT, Cawthon RM, Damcott CM, Wu S-H, Ott S, Garant MJ, et al. Telomere length is paternally inherited and is associated with parental lifespan. Proc Natl Acad Sci USA 2007;104:12135–9. CrossrefGoogle Scholar

  • 46.

    Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, Buxton JL, et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet 2013;45:422–7, 427e1–2. CrossrefPubMedGoogle Scholar

  • 47.

    Gu J, Chen M, Shete S, Amos CI, Kamat A, Ye Y, et al. A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. Cancer Prev Res (Phila) 2011;4:514–21. CrossrefPubMedGoogle Scholar

  • 48.

    Levy D, Neuhausen SL, Hunt SC, Kimura M, Hwang S-J, Chen W, et al. Genome-wide association identifies OBFC1 as a locus involved in human leukocyte telomere biology. Proc Natl Acad Sci USA 2010;107:9293–8. CrossrefGoogle Scholar

  • 49.

    Liu Y, Cao L, Li Z, Zhou D, Liu W, Shen Q, et al. A genome-wide association study identifies a locus on TERT for mean telomere length in Han Chinese. PLoS One 2014;9:e85043. CrossrefGoogle Scholar

  • 50.

    Mangino M, Hwang S-J, Spector TD, Hunt SC, Kimura M, Fitzpatrick AL, et al. Genome-wide meta-analysis points to CTC1 and ZNF676 as genes regulating telomere homeostasis in humans. Hum Mol Genet 2012;21:5385–94. PubMedCrossrefGoogle Scholar

  • 51.

    Mangino M, Richards JB, Soranzo N, Zhai G, Aviv A, Valdes AM, et al. A genome-wide association study identifies a novel locus on chromosome 18q12.2 influencing white cell telomere length. J Med Genet 2009;46:451–4. CrossrefPubMedGoogle Scholar

  • 52.

    Pooley KA, Bojesen SE, Weischer M, Nielsen SF, Thompson D, Amin Al Olama A, et al. A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk. Hum Mol Genet 2013;22:5056–64. PubMedCrossrefGoogle Scholar

  • 53.

    Prescott J, Kraft P, Chasman DI, Savage SA, Mirabello L, Berndt SI, et al. Genome-wide association study of relative telomere length. PLoS One 2011;6:e19635. PubMedCrossrefGoogle Scholar

  • 54.

    Saxena R, Bjonnes A, Prescott J, Dib P, Natt P, Lane J, et al. Genome-wide association study identifies variants in casein kinase II (CSNK2A2) to be associated with leukocyte telomere length in a Punjabi Sikh diabetic cohort. Circ Cardiovasc Genet 2014;7:287–95. CrossrefGoogle Scholar

  • 55.

    Codd V, Mangino M, van der Harst P, Braund PS, Kaiser M, Beveridge AJ, et al. Variants near TERC are associated with mean telomere length. Nat Genet 2010;42:197–9. PubMedCrossrefGoogle Scholar

  • 56.

    Lee JH, Cheng R, Honig LS, Feitosa M, Kammerer CM, Kang MS, et al. Genome wide association and linkage analyses identified three loci – 4q25, 17q23.2, and 10q11.21 – associated with variation in leukocyte telomere length: the Long Life Family Study. Front Genet 2014;4:310. Google Scholar

  • 57.

    Zeiger AM, White MJ, Eng C, Oh SS, Witonsky J, Goddard PC, et al. Genetic determinants of telomere length in African American youth. Sci Rep 2018;8:13265. PubMedCrossrefGoogle Scholar

  • 58.

    Stathopoulou MG, Petrelis AM, Buxton JL, Froguel P, Blakemore AI, Visvikis-Siest S. Genetic determinants of leucocyte telomere length in children: a neglected and challenging field. Paediatr Perinat Epidemiol 2015;29:146–50. CrossrefPubMedGoogle Scholar

  • 59.

    Weng Q, Du J, Yu F, Huang T, Chen M, Lv H, et al. The known genetic loci for telomere length may be involved in the modification of telomeres length after birth. Sci Rep 2016;6:38729. PubMedCrossrefGoogle Scholar

  • 60.

    Vaziri H, Schachter F, Uchida I, Wei L, Zhu X, Effros R, et al. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet 1993;52:661–7. PubMedGoogle Scholar

  • 61.

    Frenck RW Jr., Blackburn EH, Shannon KM. The rate of telomere sequence loss in human leukocytes varies with age. Proc Natl Acad Sci USA 1998;95:5607–10. CrossrefGoogle Scholar

  • 62.

    Zeichner SL, Palumbo P, Feng Y, Xiao X, Gee D, Sleasman J, et al. Rapid telomere shortening in children. Blood 1999;93:2824–30. PubMedGoogle Scholar

  • 63.

    Friedrich U, Schwab M, Griese EU, Fritz P, Klotz U. Telomeres in neonates: new insights in fetal hematopoiesis. Pediatr Res 2001;49:252–6. CrossrefPubMedGoogle Scholar

  • 64.

    Akkad A, Hastings R, Konje JC, Bell SC, Thurston H, Williams B. Telomere length in small-for-gestational-age babies. BJOG 2006;113:318–23. PubMedCrossrefGoogle Scholar

  • 65.

    Wojcicki JM, Shiboski S, Heyman MB, Elwan D, Lin J, Blackburn E, et al. Telomere length change plateaus at 4 years of age in Latino children: associations with baseline length and maternal change. Mol Genet Genomics 2016;291:1379–89. PubMedCrossrefGoogle Scholar

  • 66.

    Vasu V, Turner KJ, George S, Greenall J, Slijepcevic P, Griffin DK. Preterm infants have significantly longer telomeres than their term born counterparts. PLoS One 2017;12:e0180082. PubMedCrossrefGoogle Scholar

  • 67.

    Holmes DK, Bellantuono I, Walkinshaw SA, Alfirevic Z, Johnston TA, Subhedar NV, et al. Telomere length dynamics differ in foetal and early post-natal human leukocytes in a longitudinal study. Biogerontology 2009;10:279–84. CrossrefGoogle Scholar

  • 68.

    Eastwood JR, Mulder E, Verhulst S, Peters A. Increasing the accuracy and precision of relative telomere length estimates by RT qPCR. Mol Ecol Resour 2018;18:68–78. CrossrefGoogle Scholar

  • 69.

    Youngren K, Jeanclos E, Aviv H, Kimura M, Stock J, Hanna M, et al. Synchrony in telomere length of the human fetus. Hum Genet 1998;102:640–3. PubMedCrossrefGoogle Scholar

  • 70.

    Kimura M, Gazitt Y, Cao X, Zhao X, Lansdorp PM, Aviv A. Synchrony of telomere length among hematopoietic cells. Exp Hematol 2010;38:854–9. PubMedCrossrefGoogle Scholar

  • 71.

    Wright DL, Jones EL, Mayer JF, Oehninger S, Gibbons WE, Lanzendorf SE. Characterization of telomerase activity in the human oocyte and preimplantation embryo. Mol Hum Reprod 2001;7:947–55. PubMedCrossrefGoogle Scholar

  • 72.

    Ponsot E, Lexell J, Kadi F. Skeletal muscle telomere length is not impaired in healthy physically active old women and men. Muscle Nerve 2008;37:467–72. PubMedCrossrefGoogle Scholar

  • 73.

    Decary S, Mouly V, Hamida CB, Sautet A, Barbet JP, Butler-Browne GS. Replicative potential and telomere length in human skeletal muscle: implications for satellite cell-mediated gene therapy. Hum Gene Ther 1997;8:1429–38. PubMedCrossrefGoogle Scholar

  • 74.

    Benetos A, Kimura M, Labat C, Buchoff GM, Huber S, Labat L, et al. A model of canine leukocyte telomere dynamics. Aging Cell 2011;10:991–5. CrossrefPubMedGoogle Scholar

  • 75.

    Daniali L, Benetos A, Susser E, Kark JD, Labat C, Kimura M, et al. Telomeres shorten at equivalent rates in somatic tissues of adults. Nat Commun 2013;4:1597. CrossrefPubMedGoogle Scholar

  • 76.

    Aviv A, Kark JD, Susser E. Telomeres, atherosclerosis, and human longevity: a causal hypothesis. Epidemiology 2015;26:295. CrossrefPubMedGoogle Scholar

  • 77.

    Sabharwal S, Verhulst S, Guirguis G, Kark JD, Labat C, Roche NE, et al. Telomere length dynamics in early life: the blood-and-muscle model. FASEB J 2017;32:529–34. PubMedGoogle Scholar

  • 78.

    Gardner M, Bann D, Wiley L, Cooper R, Hardy R, Nitsch D, et al. Gender and telomere length: systematic review and meta-analysis. Exp Gerontol 2014;51:15–27. PubMedCrossrefGoogle Scholar

  • 79.

    Hansen ME, Hunt SC, Stone RC, Horvath K, Herbig U, Ranciaro A, et al. Shorter telomere length in Europeans than in Africans due to polygenetic adaptation. Hum Mol Genet 2016;25:2324–30. CrossrefPubMedGoogle Scholar

  • 80.

    Lynch SM, Peek MK, Mitra N, Ravichandran K, Branas C, Spangler E, et al. Race, ethnicity, psychosocial factors, and telomere length in a multicenter setting. PLoS One 2016;11:e0146723. CrossrefGoogle Scholar

  • 81.

    Kimura M, Cherkas LF, Kato BS, Demissie S, Hjelmborg JB,Brimacombe M, et al. Offspring’s leukocyte telomere length, paternal age, and telomere elongation in sperm. PLoS Genet 2008;4:e37. CrossrefPubMedGoogle Scholar

  • 82.

    Prescott J, Du M, Wong JY, Han J, De Vivo I. Paternal age at birth is associated with offspring leukocyte telomere length in the Nurses’ Health Study. Hum Reprod 2012;27:3622–31. CrossrefPubMedGoogle Scholar

  • 83.

    Muezzinler A, Mons U, Dieffenbach AK, Butterbach K, Saum KU, Schick M, et al. Smoking habits and leukocyte telomere length dynamics among older adults: results from the ESTHER cohort. Exp Gerontol 2015;70:18–25. PubMedCrossrefGoogle Scholar

  • 84.

    Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005;366:662–4. PubMedCrossrefGoogle Scholar

  • 85.

    Sassenroth D, Meyer A, Salewsky B, Kroh M, Norman K, Steinhagen-Thiessen E, et al. Sports and exercise at different ages and leukocyte telomere length in later life – data from the Berlin Aging Study II (BASE-II). PLoS One 2015;10:e0142131. PubMedCrossrefGoogle Scholar

  • 86.

    Coimbra BM, Carvalho CM, Moretti PN, Mello MF, Belangero SI. Stress-related telomere length in children: a systematic review. J Psychiatr Res 2017;92:47–54. CrossrefPubMedGoogle Scholar

  • 87.

    Edmonds GW, Hampson SE, Côté HC, Hill PL, Klest B. Childhood personality, betrayal trauma, and leukocyte telomere length in adulthood: a lifespan perspective on conscientiousness and betrayal traumas as predictors of a biomarker of cellular ageing. Eur J Pers 2016;30:426–37. CrossrefGoogle Scholar

  • 88.

    Lindqvist D, Epel ES, Mellon SH, Penninx BW, Révész D, Verhoeven JE, et al. Psychiatric disorders and leukocyte telomere length: underlying mechanisms linking mental illness with cellular aging. Neurosci Biobehav Rev 2015;55:333–64. PubMedCrossrefGoogle Scholar

  • 89.

    Ma D, Zhu W, Hu S, Yu X, Yang Y. Association between oxidative stress and telomere length in type 1 and type 2 diabetic patients. J Endocrinol Invest 2013;36:1032–7. PubMedGoogle Scholar

  • 90.

    Babizhayev MA, Vishnyakova KS, Yegorov YE. Oxidative damage impact on aging and age-related diseases: drug targeting of telomere attrition and dynamic telomerase activity flirting with imidazole-containing dipeptides. Recent Pat Drug Deliv Formul 2014;8:163–92. PubMedCrossrefGoogle Scholar

  • 91.

    Entringer S, Buss C, Wadhwa PD. Prenatal stress, telomere biology, and fetal programming of health and disease risk. Sci Signal 2012;5:pt12. PubMedGoogle Scholar

  • 92.

    Aviv A. The mitochondrial genome, paternal age and telomere length in humans. Philos Trans R Soc Lond B Biol Sci 2018;373. PubMedGoogle Scholar

  • 93.

    Salihu HM, King LM, Nwoga C, Paothong A, Pradhan A, Marty PJ, et al. Association between maternal-perceived psychological stress and fetal telomere length. South Med J 2016;109:767–72. PubMedCrossrefGoogle Scholar

  • 94.

    Marchetto NM, Glynn RA, Ferry ML, Ostojic M, Wolff SM, Yao R, et al. Prenatal stress and newborn telomere length. Am J Obstet Gynecol 2016;215:94.e1–8. CrossrefGoogle Scholar

  • 95.

    Send TS, Gilles M, Codd V, Wolf I, Bardtke S, Streit F, et al. Telomere length in newborns is related to maternal stress during pregnancy. Neuropsychopharmacology 2017;42:2407–13. CrossrefPubMedGoogle Scholar

  • 96.

    Entringer S, Epel ES, Lin J, Blackburn EH, Buss C, Simhan HN, et al. Maternal estriol concentrations in early gestation predict infant telomere length. J Clin Endocrinol Metab 2015;100:267–73. CrossrefPubMedGoogle Scholar

  • 97.

    Almanzar G, Eberle G, Lassacher A, Specht C, Koppelstaetter C, Heinz-Erian P, et al. Maternal cigarette smoking and its effect on neonatal lymphocyte subpopulations and replication. BMC Pediatr 2013;13:57. PubMedCrossrefGoogle Scholar

  • 98.

    Jones CW, Gambala C, Esteves KC, Wallace M, Schlesinger R, O’Quinn M, et al. Differences in placental telomere length suggest a link between racial disparities in birth outcomes and cellular aging. Am J Obstet Gynecol 2017;216:294.e1–8. CrossrefGoogle Scholar

  • 99.

    Kim JH, Kim GJ, Lee D, Ko JH, Lim I, Bang H, et al. Higher maternal vitamin D concentrations are associated with longer leukocyte telomeres in newborns. Matern Child Nutr 2018;14:1. Google Scholar

  • 100.

    Entringer S, Epel ES, Lin J, Blackburn EH, Buss C, Shahbaba B, et al. Maternal folate concentration in early pregnancy and newborn telomere length. Ann Nutr Metab 2015;66:202–8. PubMedCrossrefGoogle Scholar

  • 101.

    Martens DS, Plusquin M, Gyselaers W, De Vivo I, Nawrot TS. Maternal pre-pregnancy body mass index and newborn telomere length. BMC Med 2016;14:148. CrossrefPubMedGoogle Scholar

  • 102.

    Wojcicki JM, Olveda R, Heyman MB, Elwan D, Lin J, Blackburn E, et al. Cord blood telomere length in Latino infants: relation with maternal education and infant sex. J Perinatol 2016;36:235–41. PubMedCrossrefGoogle Scholar

  • 103.

    Drury SS, Esteves K, Hatch V, Woodbury M, Borne S, Adamski A, et al. Setting the trajectory: racial disparities in newborn telomere length. J Pediatr 2015;166:1181–6. CrossrefPubMedGoogle Scholar

  • 104.

    Entringer S, Epel ES, Lin J, Buss C, Shahbaba B, Blackburn EH, et al. Maternal psychosocial stress during pregnancy is associated with newborn leukocyte telomere length. Am J Obstet Gynecol 2013;208:134.e1–7. CrossrefGoogle Scholar

  • 105.

    Salihu HM, Pradhan A, King L, Paothong A, Nwoga C, Marty PJ, et al. Impact of intrauterine tobacco exposure on fetal telomere length. Am J Obstet Gynecol 2015;212:205.e1–8. CrossrefGoogle Scholar

  • 106.

    Cross JA, Temple RC, Hughes JC, Dozio NC, Brennan C, Stanley K, et al. Cord blood telomere length, telomerase activity and inflammatory markers in pregnancies in women with diabetes or gestational diabetes. Diabet Med 2010;27:1264–70. CrossrefPubMedGoogle Scholar

  • 107.

    Xu J, Ye J, Wu Y, Zhang H, Luo Q, Han C, et al. Reduced fetal telomere length in gestational diabetes. PLoS One 2014;9:e86161. PubMedCrossrefGoogle Scholar

  • 108.

    Gilfillan C, Naidu P, Gunawan F, Hassan F, Tian P, Elwood N. Leukocyte telomere length in the neonatal offspring of mothers with gestational and pre-gestational diabetes. PLoS One 2016;11:e0163824. Google Scholar

  • 109.

    Factor-Litvak P, Susser E, Kezios K, McKeague I, Kark JD, Hoffman M, et al. Leukocyte telomere length in newborns: implications for the role of telomeres in human disease. Pediatrics 2016;137:e20153927. PubMedCrossrefGoogle Scholar

  • 110.

    Mayer S, Bruderlein S, Perner S, Waibel I, Holdenried A, Ciloglu N, et al. Sex-specific telomere length profiles and age-dependent erosion dynamics of individual chromosome arms in humans. Cytogenet Genome Res 2006;112:194–201. PubMedCrossrefGoogle Scholar

  • 111.

    Moller P, Mayer S, Mattfeldt T, Muller K, Wiegand P, Bruderlein S. Sex-related differences in length and erosion dynamics of human telomeres favor females. Aging (Albany NY) 2009;1:733–9. PubMedGoogle Scholar

  • 112.

    Barrett EL, Richardson DS. Sex differences in telomeres and lifespan. Aging Cell 2011;10:913–21. CrossrefPubMedGoogle Scholar

  • 113.

    Benetos A, Dalgard C, Labat C, Kark JD, Verhulst S, Christensen K, et al. Sex difference in leukocyte telomere length is ablated in opposite-sex co-twins. Int J Epidemiol 2014;43:1799–805. PubMedCrossrefGoogle Scholar

  • 114.

    Galtier-Dereure F, Boegner C, Bringer J. Obesity and pregnancy: complications and cost. Am J Clin Nutr 2000;71:1242S–8S. PubMedCrossrefGoogle Scholar

  • 115.

    McCloskey K, Ponsonby AL, Collier F, Allen K, Tang ML, Carlin JB, et al. The association between higher maternal pre-pregnancy body mass index and increased birth weight, adiposity and inflammation in the newborn. Pediatr Obes 2018;13:46–53. CrossrefPubMedGoogle Scholar

  • 116.

    Humphreys J, Epel ES, Cooper BA, Lin J, Blackburn EH, Lee KA. Telomere shortening in formerly abused and never abused women. Biol Res Nurs 2012;14:115–23. CrossrefPubMedGoogle Scholar

  • 117.

    Parks CG, Miller DB, McCanlies EC, Cawthon RM, Andrew ME, DeRoo LA, et al. Telomere length, current perceived stress, and urinary stress hormones in women. Cancer Epidemiol Biomarkers Prev 2009;18:551–60. CrossrefPubMedGoogle Scholar

  • 118.

    Entringer S, Epel ES, Kumsta R, Lin J, Hellhammer DH, Blackburn EH, et al. Stress exposure in intrauterine life is associated with shorter telomere length in young adulthood. Proc Natl Acad Sci USA 2011;108:E513–8. CrossrefGoogle Scholar

  • 119.

    Astuti Y, Wardhana A, Watkins J, Wulaningsih W. Cigarette smoking and telomere length: a systematic review of 84 studies and meta-analysis. Environ Res 2017;158:480–9. CrossrefPubMedGoogle Scholar

  • 120.

    Babizhayev MA, Savel’yeva EL, Moskvina SN, Yegorov YE. Telomere length is a biomarker of cumulative oxidative stress, biologic age, and an independent predictor of survival and therapeutic treatment requirement associated with smoking behavior. Am J Ther 2011;18:e209–26. CrossrefPubMedGoogle Scholar

  • 121.

    Lee D-C, Im J-A, Kim J-H, Lee H-R, Shim J-Y. Effect of long-term hormone therapy on telomere length in postmenopausal women. Yonsei Med J 2005;46:471–9. PubMedCrossrefGoogle Scholar

  • 122.

    Townsley DM, Dumitriu B, Liu D, Biancotto A, Weinstein B, Chen C, et al. Danazol treatment for telomere diseases. N Engl J Med 2016;374:1922–31. CrossrefPubMedGoogle Scholar

  • 123.

    Unryn BM, Cook LS, Riabowol KT. Paternal age is positively linked to telomere length of children. Aging Cell 2005;4:97–101. PubMedCrossrefGoogle Scholar

About the article

Corresponding author: Dr. Sophie Visvikis-Siest, University of Lorraine, Inserm, IGE-PCV, 30 rue Lionnois, 54000 Nancy, France, Phone: +33 6 07 60 25 69

Received: 2019-03-01

Accepted: 2019-07-30

Published Online: 2019-08-29

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: Financial support was provided by the European Union within the frames of the Operational Programme FEDER-FSE Lorraine et Massif des Vosges 2014–2020, by Agence Nationale de la Recherche, programme d’Investissements d’avenir, grant number ANR-15RHU-0004 and GEENAGE project “(Functional Genomic, Epigenomic and ENvironment interplay to IMPACT management of healthy and pathological AGEing)” within the frames of the LUE project (Lorraine University of Excellence). Additionally, this work was supported by the regional project CPER-ITM2P 2015–2020.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organisation(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), 20190235, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2019-0235.

Export Citation

©2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in